Pancreatic Cancer Research

ResearcherGerman Cancer Research CenterActive in the last 2 years

Rainer Fietkau

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8295-7145; OpenAlex author ID A5027231637. Sources: OpenAlex.

Their work

Papers
10 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
29
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 1 paper · 2014: none · 2015: 1 paper · 2016: none · 2017: none · 2018: 2 papers · 2019: none · 2020: none · 2021: 1 paper · 2022: none · 2023: 1 paper · 2024: none · 2025: 1 paper · 2026: 2 papers

Papers 10

  1. Reply to: "Chemoradiotherapy in Pancreatic Cancer: Toward Precision Oncology," "Key Methodological Considerations in the Interpretation of the CONKO-007 Trial,… Co-author DOI 10.1200/jco-25-02926↗
  2. Erratum: Benefit of Chemoradiotherapy Versus Chemotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer: The Randomi… Co-author DOI 10.1200/jco-25-03004↗
  3. Benefit of Chemoradiotherapy Versus Chemotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer: The Randomized CONKO… Co-author DOI 10.1200/jco-24-01502↗
  4. Regional hyperthermia with cisplatin added to gemcitabine versus gemcitabine in patients with resected pancreatic ductal adenocarcinoma: The HEAT randomised cl… Co-author DOI 10.1016/j.ejca.2022.12.009↗
  5. R0 resection following chemo (radio)therapy improves survival of primary inoperable pancreatic cancer patients. Interim results of the German randomized CONKO-… Co-author DOI 10.1007/s00066-020-01680-2↗
  6. Essential role of radiation therapy for the treatment of pancreatic cancer : Novel study concepts and established treatment recommendations. Co-author DOI 10.1007/s00066-017-1227-5↗
  7. Cytotoxic effect of Efavirenz in BxPC-3 pancreatic cancer cells is based on oxidative stress and is synergistic with ionizing radiation. Co-author DOI 10.3892/ol.2017.7523↗
  8. Efavirenz Has the Highest Anti-Proliferative Effect of Non-Nucleoside Reverse Transcriptase Inhibitors against Pancreatic Cancer Cells. Co-author DOI 10.1371/journal.pone.0130277↗
  9. [S3-guideline exocrine pancreatic cancer]. Co-author DOI 10.1055/s-0033-1356220↗
  10. Gemcitabine/cisplatin versus 5-fluorouracil/mitomycin C chemoradiotherapy in locally advanced pancreatic cancer: a retrospective analysis of 93 patients. Last author DOI 10.1186/1748-717x-6-88↗

Closest collaborators

The 25 strongest of 29 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Helmut Oettle · 5 shared papers, 2021–2026 · strength 1.00
  2. Sabine Semrau · 4 shared papers, 2021–2026 · strength 0.89
  3. Stefan Hubert Boeck · 4 shared papers, 2021–2026 · strength 0.62
  4. Markus Hecht · 4 shared papers, 2015–2026 · strength 0.53
  5. Michael B. Ghadimi · 3 shared papers, 2021–2026 · strength 0.50
  6. Dorota Łubgan · 3 shared papers, 2021–2026 · strength 0.50
  7. Waldemar H. Uhl · 3 shared papers, 2021–2026 · strength 0.50
  8. Henriette Golcher · 3 shared papers, 2021–2026 · strength 0.50
  9. Robert Grützmann · 3 shared papers, 2021–2026 · strength 0.50
  10. Anke Reinacher‐Schick · 3 shared papers, 2021–2026 · strength 0.50
  11. Uwe A. Wittel · 3 shared papers, 2021–2026 · strength 0.50
  12. Andrea Tannapfel · 2 shared papers, 2025–2026 · strength 0.40
  13. Dirk Waldschmidt · 2 shared papers, 2025–2026 · strength 0.40
  14. Luitpold Valentin Distel · 2 shared papers, 2015–2018 · strength 0.13
  15. Sophie Dobiasch · 1 shared paper, 2018 · strength 0.12
  16. Stephanie Elisabeth Combs · 1 shared paper, 2018 · strength 0.12
  17. Marcus Bahra · 1 shared paper, 2023 · strength 0.11
  18. Katharina Tschoep · 1 shared paper, 2023 · strength 0.11
  19. Wolfgang Erwin Thasler · 1 shared paper, 2023 · strength 0.11
  20. Pirus Ghadjar · 1 shared paper, 2023 · strength 0.11
  21. Rolf Dieter Issels · 1 shared paper, 2023 · strength 0.11
  22. Lucjan Stanislaw Wyrwicz · 1 shared paper, 2023 · strength 0.11
  23. Wolfram Trudo Knoefel · 1 shared paper, 2023 · strength 0.11
  24. Volker Heinemann · 1 shared paper, 2023 · strength 0.11
  25. Uwe Pelzer · 1 shared paper, 2023 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.